Membraneblue is a drug owned by Dorc International Bv. It is protected by 2 US drug patents filed in 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 12, 2019. Details of Membraneblue's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6372449 | Opthalmic methods and uses |
Nov, 2019
(5 years ago) |
Expired
|
| US6696430 | Use of vital dye for facilitating surgical procedures for vitreo-retinal surgery |
May, 2019
(5 years ago) |
Expired
|
FDA has granted several exclusivities to Membraneblue. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Membraneblue, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Membraneblue.
Exclusivity Information
Membraneblue holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Membraneblue's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 20, 2016 |
US patents provide insights into the exclusivity only within the United States, but Membraneblue is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Membraneblue's family patents as well as insights into ongoing legal events on those patents.
Membraneblue's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Membraneblue's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 12, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Membraneblue Generics:
There are no approved generic versions for Membraneblue as of now.
Alternative Brands for Membraneblue
Membraneblue which is used for aiding in the identification and removal of intraocular membranes during ophthalmic surgery., has several other brand drugs using the same active ingredient (Trypan Blue). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Dorc |
|
About Membraneblue
Membraneblue is a drug owned by Dorc International Bv. It is used for aiding in the identification and removal of intraocular membranes during ophthalmic surgery. Membraneblue uses Trypan Blue as an active ingredient. Membraneblue was launched by Dorc in 2009.
Approval Date:
Membraneblue was approved by FDA for market use on 20 February, 2009.
Active Ingredient:
Membraneblue uses Trypan Blue as the active ingredient. Check out other Drugs and Companies using Trypan Blue ingredient
Treatment:
Membraneblue is used for aiding in the identification and removal of intraocular membranes during ophthalmic surgery.
Dosage:
Membraneblue is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.15% | SOLUTION | Discontinued | OPHTHALMIC |